In the rapidly evolving landscape of gender-affirming care, a critical blind spot has emerged, threatening the long-term health outcomes of transgender and gender diverse (TGD) individuals. A groundbreaking study conducted by researchers at the Boston University Chobanian & Avedisian School of Medicine has identified profound systemic barriers that prevent TGD patients from receiving essential breast and chest cancer risk assessments prior to undergoing gender-affirming mastectomy—commonly referred to as "top surgery."
As surgical volumes for gender-affirming procedures rise, the medical community is grappling with a stark reality: many patients are entering the operating room without an understanding of how their procedure will impact their lifelong cancer risk, or whether they carry genetic predispositions that should fundamentally alter their surgical approach. The findings, published in the journal Breast Cancer Research and Treatment, highlight an urgent need for structural reform in how oncology and gender-affirming care intersect.
The Landscape of Disparity: Main Facts
The core issue identified by the researchers is not a lack of empathy among healthcare providers, but a systemic failure of institutional infrastructure. TGD individuals already face significant healthcare disparities across the oncology spectrum. These are compounded by a complex web of past harmful experiences in clinical settings, a volatile sociopolitical climate that complicates access to care, and a lack of standardized clinical guidelines.
Currently, when a patient seeks a gender-affirming mastectomy, the focus is almost exclusively on the surgical outcome and the relief of gender dysphoria. While these are vital, the conversation often neglects the "after": how the removal of breast tissue affects future cancer screening protocols and how family history—if unknown or ignored—might necessitate a more extensive surgical approach to mitigate cancer risk.
The research team, led by genetic counselor and assistant professor Kim Zayhowski, MS, CGC, emphasizes that every patient, regardless of gender identity, deserves clear, actionable data regarding their cancer risk. Without this, TGD individuals are significantly more likely to be diagnosed with cancer at later, more dangerous stages than their cisgender counterparts.
Chronology of a Crisis: From Patient Experience to Systemic Failure
The road to these findings was paved by a two-phase qualitative research project that spanned years of investigation into the current gaps in the healthcare system.
Phase I: Listening to the Patient Voice
In a previous companion study, researchers interviewed 16 transgender patients about their journeys through the gender-affirming surgical process. The results were consistent and troubling: patients reported a systemic lack of information. They often felt that the surgical team was ill-equipped to discuss the nuances of hereditary cancer risk or the implications of the surgery on future screening. Many reported that they were not asked about family cancer histories in a way that felt relevant to their surgical planning, leaving them to navigate the intersection of oncology and gender identity alone.
Phase II: The Provider Perspective
Building on the patient findings, the current study turned the lens toward the healthcare professionals themselves. The team conducted interviews with 20 professionals, including primary care physicians, genetic counselors, oncologists, and plastic surgeons. The goal was to identify why these gaps exist in clinical practice.
The interviews revealed that while many providers expressed a sincere desire to support their patients, they were operating in a vacuum. There is a lack of standardized, evidence-based pathways for cancer risk assessment in the context of gender-affirming care. Most providers reported that they did not have the institutional support or the formal training to initiate these complex, multi-disciplinary conversations.
Supporting Data and the Call for Institutional Accountability
The research team identified four pillars necessary to dismantle these barriers:
- Clear Institutional Accountability: Moving the burden of care from the individual provider to the hospital system.
- Harmonized Evidence-Based Guidelines: Establishing clinical standards that are universally recognized.
- Standardized Care Pathways: Creating a "roadmap" for the patient journey that includes routine oncology screenings.
- Embedded Genetic Counseling: Integrating genetics professionals into the multidisciplinary teams that manage gender-affirming care.
The study argues that relying on individual provider commitment is insufficient. In a field as specialized as gender-affirming surgery, "ad-hoc" care is dangerous. When a patient arrives for a consultation, the system should be designed to automatically trigger a risk assessment. This includes a review of hereditary factors that could indicate a higher risk for breast or chest cancer, which might lead to a recommendation for prophylactic tissue removal beyond what is traditionally performed for gender affirmation.
Official Perspectives: Addressing the Infrastructure Gap
Kim Zayhowski, the study’s corresponding author, has been vocal about the systemic nature of the problem. "We’re calling on healthcare institutions and organizations to move beyond reliance on individual provider commitment," Zayhowski stated. "They must invest in the institutional infrastructure necessary to guarantee that trans patients receive comprehensive cancer risk information to make truly informed decisions about their care."
The researchers stress that the current system is not built to serve this population. The disconnect between plastic surgery, endocrinology, and oncology creates "silos" of care. When a patient sees a surgeon for a mastectomy, the surgeon may not be trained in hereditary cancer risk, and the primary care physician may not be involved in the pre-surgical planning. This lack of communication is where the most critical information—information that could save a life—is lost.
Implications for the Future: The CHESTcare Toolkit
In response to these findings, the research team is not merely diagnosing the problem; they are actively building the solution. They are currently developing CHESTcare (Cancer & Hereditary Risk Education & Support for Transgender and nonbinary individuals).
CHESTcare is designed as an online, comprehensive toolkit that integrates cancer and hereditary risk education with practical support for decision-making. The project aims to provide:
- Resources for Patients: Empowering TGD individuals to advocate for themselves by providing them with the right questions to ask their surgeons and physicians.
- Resources for Providers: Offering clinical guidance and best practices for integrating cancer risk assessment into the standard gender-affirming care pathway.
By bridging the information gap, the team hopes to standardize the conversation. Whether it is determining the necessity of post-surgical imaging or deciding on the extent of tissue removal based on a genetic predisposition, the toolkit aims to make "informed consent" a reality for all patients, not just those who happen to have access to a knowledgeable provider.
Broadening the Horizon: A Shift in Oncology Care
The implications of this research extend far beyond the operating room. As the medical community moves toward a model of personalized medicine, the exclusion of TGD individuals from established cancer screening protocols is a significant oversight.
The findings published in Breast Cancer Research and Treatment serve as a wake-up call to hospitals, health systems, and professional medical associations. The "standard of care" must be redefined to include the specific, intersectional needs of transgender and nonbinary populations. Without such changes, the healthcare system continues to perpetuate a cycle where a life-changing, identity-affirming surgery is inadvertently coupled with a long-term risk that the patient was never given the opportunity to manage.
As the team at Boston University continues their work, the medical community will be watching. With the backing of the National Society of Genetic Counsellors Cancer Special Interest Group, this project represents a significant step toward equity. The goal is clear: a future where the transition journey is supported by a robust, informed, and inclusive approach to long-term health, ensuring that every patient can move forward with confidence, clarity, and the highest standard of medical care.
This article summarizes findings from "Barriers to breast/chest cancer risk assessment in gender-affirming care," published in Breast Cancer Research and Treatment. For more information on the evolving standards of care for transgender and nonbinary individuals, readers are encouraged to consult the forthcoming resources at CHESTcare.org.
About the Author
